Recombinant Bacille Calmette-Guérin (BCG) Expressing Human Interferon-alpha 2B Demonstrates Enhanced Immunogenicity

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2001 Feb 24

PMID 11207657

Citations 21

Authors

Y Luo

X Chen

R Han

M A ODonnell

Affiliations

Soon will be listed here.

Abstract

To increase its immunostimulatory properties, BCG was genetically engineered to secrete recombinant human interferon-alpha 2B (rhIFN-alpha) under control of the mycobacterial heat shock protein (hsp)60 promoter and the alpha antigen signal sequence. Expression of rhIFN-alpha was readily detectable by ELISA and on Western blotting. When compared with control BCG, rhIFN-alpha BCG was substantially more active in inducing the production of IFN-gamma and IFN-inducible protein 10 (IP-10) from human peripheral blood mononuclear cells, while IL-10 production was correspondingly decreased. These effects were reversible upon antibody neutralization of rhIFN-alpha. Among 10 patients tested, rhIFN-alpha BCG enhanced IFN-gamma production in all patients ranging from 1.4- to 23.7-fold with a general trend toward greatest enhancement among those with weakest baseline responses to control BCG. Correspondingly, rhIFN-alpha BCG decreased IL-10 production in all patients by 1.2-4.8-fold. The onset of IFN-gamma production induced by rhIFN-alpha BCG was also more rapid, occurring within 4 h after stimulation versus > 24 h with wild-type BCG. The observation that the maximum IFN-gamma induction depends on the simultaneous presence of both IFN-alpha and BCG highlights the advantages of rhIFN-alpha BCG. Taken together, these immunostimulatory properties of rhIFN-alpha BCG suggest that it may be a superior agent for immunotherapeutic protocols involving live BCG in humans.

Citing Articles

Recombinant BCG to Enhance Its Immunomodulatory Activities.

Kowalewicz-Kulbat M, Locht C Vaccines (Basel). 2022; 10(5).

PMID: 35632582 PMC: 9143156. DOI: 10.3390/vaccines10050827.

Recombinant coexpressing Ag85B-IFN-γ enhances the cell-mediated immunity in C57BL/6 mice.

Liu W, Xu Y, Shen H, Yan J, Yang E, Wang H Exp Ther Med. 2017; 13(5):2339-2347.

PMID: 28565847 PMC: 5443280. DOI: 10.3892/etm.2017.4273.

Nonmuscle invasive bladder cancer: a primer on immunotherapy.

Maruf M, Brancato S, Agarwal P Cancer Biol Med. 2016; 13(2):194-205.

PMID: 27458527 PMC: 4944546. DOI: 10.20892/j.issn.2095-3941.2016.0020.

Novel immunotherapeutic approaches to the treatment of urothelial carcinoma.

Muthigi A, George A, Brancato S, Agarwal P Ther Adv Urol. 2016; 8(3):203-14.

PMID: 27247630 PMC: 4872187. DOI: 10.1177/1756287216628784.

Manipulation of BCG vaccine: a double-edged sword.

Singh V, Srivastava R, Srivastava B Eur J Clin Microbiol Infect Dis. 2016; 35(4):535-43.

PMID: 26810060 DOI: 10.1007/s10096-016-2579-y.

References

Gan Y, Zhang Y, Khoo H, Esuvaranathan K . Antitumour immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer. Eur J Cancer. 1999; 35(7):1123-9. DOI: 10.1016/s0959-8049(99)00057-x. View

Slaton J, Perrotte P, Inoue K, Dinney C, Fidler I . Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 1999; 5(10):2726-34. View

Naitoh J, Franklin J, ODonnell M, Belldegrun A . Interferon alpha for the treatment of superficial bladder cancer. Adv Exp Med Biol. 1999; 462:371-86; discussion 387-92. DOI: 10.1007/978-1-4615-4737-2_29. View

Borden E, Groveman D, Nasu T, Reznikoff C, Bryan G . Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J Urol. 1984; 132(4):800-3. DOI: 10.1016/s0022-5347(17)49877-6. View

Ratliff T, Gillen D, Catalona W . Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol. 1987; 137(1):155-8. DOI: 10.1016/s0022-5347(17)43909-7. View

Williams R . Intravesical interferon alfa in the treatment of superficial bladder cancer. Semin Oncol. 1988; 15(5 Suppl 5):10-3. View

Sarosdy M, Kierum C . Combination immunotherapy of murine transitional cell cancer using BCG and an interferon-inducing pyrimidinone. J Urol. 1989; 142(5):1376-9. DOI: 10.1016/s0022-5347(17)39103-6. View

Bohle A, Gerdes J, Ulmer A, Hofstetter A, Flad H . Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol. 1990; 144(1):53-8. DOI: 10.1016/s0022-5347(17)39365-5. View

Tzai T, Lin S . Interferon-alpha can alter the lytic susceptibility of murine bladder transitional cell carcinoma (MBT-2) by their original poor specific cytotoxic tumor infiltrating lymphocytes. J Urol. 1992; 147(2):523-7. DOI: 10.1016/s0022-5347(17)37293-2. View

10.

Alvarez-Mon M, Molto L, Manzano L, Olivier C, Carballido J . Immunomodulatory effect of interferon-alpha 2b on natural killer cells and T lymphocytes from patients with transitional cell carcinoma of the bladder. Anticancer Drugs. 1992; 3 Suppl 1:5-8. DOI: 10.1097/00001813-199205000-00002. View

11.

Lamm D . Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am. 1992; 19(3):573-80. View

12.

SARGENT E, Williams R . Immunotherapeutic alternatives in superficial bladder cancer. Interferon, interleukin-2, and keyhole-limpet hemocyanin. Urol Clin North Am. 1992; 19(3):581-9. View

13.

Ratliff T . Role of the immune response in BCG for bladder cancer. Eur Urol. 1992; 21 Suppl 2:17-21. DOI: 10.1159/000474916. View

14.

Steg A, Adjiman S, Debre B . BCG therapy in superficial bladder tumours--complications and precautions. Eur Urol. 1992; 21 Suppl 2:35-40. DOI: 10.1159/000474920. View

15.

Brinkmann V, Heusser C, Baer J, Kilchherr E, Erard F . Interferon-alpha suppresses the capacity of T cells to help antibody production by human B cells. J Interferon Res. 1992; 12(4):267-74. DOI: 10.1089/jir.1992.12.267. View

16.

Ratliff T, Ritchey J, Yuan J, Andriole G, Catalona W . T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 1993; 150(3):1018-23. DOI: 10.1016/s0022-5347(17)35678-1. View

17.

Brinkmann V, Geiger T, Alkan S, Heusser C . Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med. 1993; 178(5):1655-63. PMC: 2191249. DOI: 10.1084/jem.178.5.1655. View

18.

ODonnell M, Aldovini A, Duda R, Yang H, Szilvasi A, Young R . Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun. 1994; 62(6):2508-14. PMC: 186538. DOI: 10.1128/iai.62.6.2508-2514.1994. View

19.

Bowyer L, Hall R, Reading J, MARSH M . The persistence of bacille Calmette-Guérin in the bladder after intravesical treatment for bladder cancer. Br J Urol. 1995; 75(2):188-92. DOI: 10.1111/j.1464-410x.1995.tb07309.x. View

20.

ODonnell M, DeWolf W . Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin N Am. 1995; 4(2):189-202. View